Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
2.
Catheter Cardiovasc Interv ; 100(1): 175-178, 2022 07.
Artículo en Inglés | MEDLINE | ID: covidwho-1802098

RESUMEN

Left ventricular (LV) unloading is an important concept in patients undergoing peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO). We present a case of a 32-year-old male in acute cardiorespiratory collapse due to coronavirus disease (COVID-19) who underwent VA-ECMO cannulation in the setting of cardiogenic shock and acute respiratory distress syndrome. Due to inability to utilize percutaneous LV assist device (pLVAD) for LV unloading due to small end diastolic dimension, alternative strategies were explored. A traditionally utilized right ventricular support device, the ProTek Duo (TandemLife, Pittsburgh, PA), was utilized to drain the pulmonary artery, leading to improvement in parameters for cardiogenic shock. To our knowledge, this is the first case in which a ProTek Duo has been utilized in conjunction with VA-ECMO to provide LV unloading in support of a patient in cardiogenic shock. This method can be employed in future challenging situations where pLVAD is not feasible.


Asunto(s)
COVID-19 , Drenaje , Insuficiencia Cardíaca , Insuficiencia Respiratoria , Adulto , COVID-19/complicaciones , Drenaje/métodos , Insuficiencia Cardíaca/terapia , Insuficiencia Cardíaca/virología , Humanos , Masculino , Arteria Pulmonar , Insuficiencia Respiratoria/terapia , Insuficiencia Respiratoria/virología , Choque Cardiogénico/terapia , Resultado del Tratamiento
3.
PLoS One ; 16(7): e0254635, 2021.
Artículo en Inglés | MEDLINE | ID: covidwho-1311289

RESUMEN

BACKGROUND: Statins have anti-inflammatory and immunomodulatory effects that may reduce the severity of coronavirus disease 2019 (COVID-19), in which organ dysfunction is mediated by severe inflammation. Large studies with diverse populations evaluating statin use and outcomes in COVID-19 are lacking. METHODS AND RESULTS: We used data from 10,541 patients hospitalized with COVID-19 through September 2020 at 104 US hospitals enrolled in the American Heart Association's COVID-19 Cardiovascular Disease (CVD) Registry to evaluate the associations between statin use and outcomes. Prior to admission, 42% of subjects (n = 4,449) used statins (7% on statins alone, 35% on statins plus anti-hypertensives). Death (or discharge to hospice) occurred in 2,212 subjects (21%). Outpatient use of statins, either alone or with anti-hypertensives, was associated with a reduced risk of death (adjusted odds ratio [aOR] 0.59, 95% CI 0.50-0.69), adjusting for demographic characteristics, insurance status, hospital site, and concurrent medications by logistic regression. In propensity-matched analyses, use of statins and/or anti-hypertensives was associated with a reduced risk of death among those with a history of CVD and/or hypertension (aOR 0.68, 95% CI 0.58-0.81). An observed 16% reduction in odds of death among those without CVD and/or hypertension was not statistically significant. CONCLUSIONS: Patients taking statins prior to hospitalization for COVID-19 had substantially lower odds of death, primarily among individuals with a history of CVD and/or hypertension. These observations support the continuation and aggressive initiation of statin and anti-hypertensive therapies among patients at risk for COVID-19, if these treatments are indicated based upon underlying medical conditions.


Asunto(s)
Antihipertensivos/administración & dosificación , COVID-19/epidemiología , Enfermedades Cardiovasculares/epidemiología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Sistema de Registros/estadística & datos numéricos , Adulto , Factores de Edad , Anciano , American Heart Association , Antihipertensivos/uso terapéutico , COVID-19/mortalidad , Enfermedades Cardiovasculares/tratamiento farmacológico , Utilización de Medicamentos/estadística & datos numéricos , Femenino , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Masculino , Persona de Mediana Edad , Mortalidad/tendencias , Grupos de Población/estadística & datos numéricos , Estados Unidos
4.
Catheter Cardiovasc Interv ; 97(2): E249-E252, 2021 02 01.
Artículo en Inglés | MEDLINE | ID: covidwho-209585

RESUMEN

A 48-year-old woman with a past medical history of migraines and hyperlipidemia presented due to severe retrosternal chest pain with no other associated signs or symptoms. The patient was hemodynamically stable and was found to have an elevated troponin with electrocardiogram showing no ischemic changes. Computed tomography of the coronary arteries showed a left dominant system with dissection extending from the mid-to-distal left anterior descending (LAD) artery. The patient was subsequently discharged on medical therapy but returned 3 days later due to worsening chest pain. Electrocardiogram revealed inferior and anteroseptal ST segment changes with peak troponin of 14.9 ng/ml (reference range <0.80 ng/ml). Coronavirus disease 2019 (COVID-19) nasopharyngeal swab was performed prior to urgent coronary angiogram. Coronary angiogram was performed with full personal protective equipment for respiratory and droplet precautions due to pending COVID-19 testing results. Angiogram revealed spontaneous coronary artery dissection (SCAD) extending from the ostium of the LAD to the distal vessel. COVID-19 testing returned positive while in intensive care unit. The patient was not a percutaneous coronary intervention candidate due to the extent of the dissection and was not a surgical candidate due to a lack of graftable target and medical management was continued. To our knowledge, this case is the first in which SCAD has been reported in the LAD in a patient with COVID-19 with no other symptoms of respiratory illness or symptoms classically associated with the novel coronavirus. SCAD should be considered on the differential as one of the various cardiac manifestations of COVID-19 infection.


Asunto(s)
COVID-19/complicaciones , COVID-19/diagnóstico , Anomalías de los Vasos Coronarios/diagnóstico , Anomalías de los Vasos Coronarios/virología , Enfermedades Vasculares/congénito , COVID-19/terapia , Angiografía Coronaria , Anomalías de los Vasos Coronarios/terapia , Electrocardiografía , Femenino , Humanos , Persona de Mediana Edad , Enfermedades Vasculares/diagnóstico , Enfermedades Vasculares/terapia , Enfermedades Vasculares/virología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA